-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 24, Fosun Pharma issued an announcement stating that its holding subsidiary, Aohong Pharmaceutical, voluntarily applied to the State Food and Drug Administration for the withdrawal of the application for registration of marketing authorization for cromolyn sodium granules, and recently received the State Food and Drug Administration’s approval for the application.
The new drug is a generic drug independently developed by the company and is intended to be mainly used for the treatment of atopic dermatitis caused by food allergies
As of the date of this announcement, cromolyn sodium oral preparations that have been marketed globally mainly include Sanofi's INTAL®, etc.
As of October 2021, the Group has invested approximately RMB 11.